IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 12.6 SEK -1.95% Market Closed
Market Cap: 652.5m SEK
Have any thoughts about
IRLAB Therapeutics AB?
Write Note

Intrinsic Value

IRLAB A's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one IRLAB A stock under the Base Case scenario is 16.17 SEK. Compared to the current market price of 12.6 SEK, IRLAB Therapeutics AB is Undervalued by 22%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IRLAB A Intrinsic Value
16.17 SEK
Undervaluation 22%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
IRLAB Therapeutics AB

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for IRLAB A cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about IRLAB A?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about IRLAB Therapeutics AB

Provide an overview of the primary business activities
of IRLAB Therapeutics AB.

What unique competitive advantages
does IRLAB Therapeutics AB hold over its rivals?

What risks and challenges
does IRLAB Therapeutics AB face in the near future?

Has there been any significant insider trading activity
in IRLAB Therapeutics AB recently?

Summarize the latest earnings call
of IRLAB Therapeutics AB.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for IRLAB Therapeutics AB.

Provide P/S
for IRLAB Therapeutics AB.

Provide P/E
for IRLAB Therapeutics AB.

Provide P/OCF
for IRLAB Therapeutics AB.

Provide P/FCFE
for IRLAB Therapeutics AB.

Provide P/B
for IRLAB Therapeutics AB.

Provide EV/S
for IRLAB Therapeutics AB.

Provide EV/GP
for IRLAB Therapeutics AB.

Provide EV/EBITDA
for IRLAB Therapeutics AB.

Provide EV/EBIT
for IRLAB Therapeutics AB.

Provide EV/OCF
for IRLAB Therapeutics AB.

Provide EV/FCFF
for IRLAB Therapeutics AB.

Provide EV/IC
for IRLAB Therapeutics AB.

Show me price targets
for IRLAB Therapeutics AB made by professional analysts.

What are the Revenue projections
for IRLAB Therapeutics AB?

How accurate were the past Revenue estimates
for IRLAB Therapeutics AB?

What are the Net Income projections
for IRLAB Therapeutics AB?

How accurate were the past Net Income estimates
for IRLAB Therapeutics AB?

What are the EPS projections
for IRLAB Therapeutics AB?

How accurate were the past EPS estimates
for IRLAB Therapeutics AB?

What are the EBIT projections
for IRLAB Therapeutics AB?

How accurate were the past EBIT estimates
for IRLAB Therapeutics AB?

Compare the revenue forecasts
for IRLAB Therapeutics AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of IRLAB Therapeutics AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of IRLAB Therapeutics AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of IRLAB Therapeutics AB compared to its peers.

Compare the P/E ratios
of IRLAB Therapeutics AB against its peers.

Discuss the investment returns and shareholder value creation
comparing IRLAB Therapeutics AB with its peers.

Analyze the financial leverage
of IRLAB Therapeutics AB compared to its main competitors.

Show all profitability ratios
for IRLAB Therapeutics AB.

Provide ROE
for IRLAB Therapeutics AB.

Provide ROA
for IRLAB Therapeutics AB.

Provide ROIC
for IRLAB Therapeutics AB.

Provide ROCE
for IRLAB Therapeutics AB.

Provide Gross Margin
for IRLAB Therapeutics AB.

Provide Operating Margin
for IRLAB Therapeutics AB.

Provide Net Margin
for IRLAB Therapeutics AB.

Provide FCF Margin
for IRLAB Therapeutics AB.

Show all solvency ratios
for IRLAB Therapeutics AB.

Provide D/E Ratio
for IRLAB Therapeutics AB.

Provide D/A Ratio
for IRLAB Therapeutics AB.

Provide Interest Coverage Ratio
for IRLAB Therapeutics AB.

Provide Altman Z-Score Ratio
for IRLAB Therapeutics AB.

Provide Quick Ratio
for IRLAB Therapeutics AB.

Provide Current Ratio
for IRLAB Therapeutics AB.

Provide Cash Ratio
for IRLAB Therapeutics AB.

What is the historical Revenue growth
over the last 5 years for IRLAB Therapeutics AB?

What is the historical Net Income growth
over the last 5 years for IRLAB Therapeutics AB?

What is the current Free Cash Flow
of IRLAB Therapeutics AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for IRLAB Therapeutics AB.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
IRLAB Therapeutics AB

Current Assets 163.4m
Cash & Short-Term Investments 98.3m
Receivables 65.1m
Non-Current Assets 51.2m
PP&E 4.4m
Intangibles 46.9m
Other Non-Current Assets -1k
Current Liabilities 142.3m
Other Current Liabilities 142.3m
Non-Current Liabilities 2.6m
Long-Term Debt 2.6m
Efficiency

Earnings Waterfall
IRLAB Therapeutics AB

Revenue
41.6m SEK
Cost of Revenue
-115.5m SEK
Gross Profit
-73.9m SEK
Operating Expenses
-45.2m SEK
Operating Income
-119.1m SEK
Other Expenses
-330k SEK
Net Income
-119.5m SEK

Free Cash Flow Analysis
IRLAB Therapeutics AB

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

IRLAB A Profitability Score
Profitability Due Diligence

IRLAB Therapeutics AB's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive 1-Year Revenue Growth
Declining ROE
Declining ROIC
16/100
Profitability
Score

IRLAB Therapeutics AB's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

IRLAB A Solvency Score
Solvency Due Diligence

IRLAB Therapeutics AB's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
55/100
Solvency
Score

IRLAB Therapeutics AB's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IRLAB A Price Targets Summary
IRLAB Therapeutics AB

There are no price targets for IRLAB A.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for IRLAB A?

Click here to dive deeper.

Dividends

IRLAB Therapeutics AB
does not pay dividends
Shareholder Yield

Current shareholder yield for IRLAB A is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

IRLAB A Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB

Country

Sweden

Industry

Pharmaceuticals

Market Cap

653.5m SEK

Dividend Yield

0%

Description

IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Contact

VASTRA GOTALANDS
Goeteborg
Arvid Wallgrens Backe 20
+46317573800
www.irlab.se

IPO

2017-02-28

Employees

37

Officers

See Also

Discover More
What is the Intrinsic Value of one IRLAB A stock?

The intrinsic value of one IRLAB A stock under the Base Case scenario is 16.17 SEK.

Is IRLAB A stock undervalued or overvalued?

Compared to the current market price of 12.6 SEK, IRLAB Therapeutics AB is Undervalued by 22%.

Back to Top